Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: Association with ras-dependent signal-transduction pathways

International Journal of Cancer

Volumn 86, Issue 2, 2000, Pages 281-288

  Kalechman, Yona ^a   Longo, Dan L ^b   Catane, Raphael ^c   Shani, Adi ^d   Albeck, Michael ^a   Sredni, Benjamin ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d KAPLAN HOSPITAL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; PACLITAXEL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; IMMUNOMODULATION; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE MARROW; CELL CYCLE; DRUG SYNERGISM; ENZYME ACTIVATION; ETHYLENES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; NEOPLASM TRANSPLANTATION; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; SIGNAL TRANSDUCTION; SPLEEN;

EID: 0034087470     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000415)86:2<281::AID-IJC20>3.0.CO;2-X     Document Type: Article

References (20)

1. BLAGOSKLONNY, M.V., CHUMAN, Y., BERGAN, R.C. and FOJO, T., Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia, 13, 1028-1036 (1999).
2. BLAGOSKLONNY, M.V., SCHULTE, T., NGUYEN, P., TREPEL, J. and NECKERS, L.M., Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-raf-1 and represents a novel c-raf-1 signal transduction pathway. Cancer Res., 56, 1851-1854 (1996).
3. BLAGOSKLONNY, M.V., SCHULTE, T.W., NGUYEN, P., MIMNAUGH, E.G., TREPEL, J. and NECKERS, L., Taxol induction of p21waf and P53 requires c-raf-1. Cancer Res., 55, 4623-4626 (1995).
4. HALDAR, S., BASU, A. and CROCE, C.M., Bcl-2 is the guardian of microtubule integrity. Cancer Res., 57, 229-233 (1997).
5. HALDAR, S., CHINTAPALLI, J. and CROCE, C.M., Taxol-induced bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56, 1253-1255 (1996).
6. HUANG, Y., SAEED SHEIKH, M., FORNACE, A.J., JR. and HOLBROOK, N.J., Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells. Oncogene, 18, 3431-3439 (1999).
7. KALECHMAN, Y., SHANI, A., DOVRAT, S., WHISNANT, J.C., METTINGER, K., ALBECK, M. and SREDNI, B., The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma. J. Immunol. 156, 1101-1109 (1996).
8. KALECHMAN, Y., SHANI, A., SOTNIK-BARKAI, I., ALBECK, M. and SREDNI, B., The protective role of ammonium trichloro(dioxyethylene-O,O′)tellurate in combination with several cytotoxic drugs acting by different mechanisms of action. Cancer Res, 53, 5962-5969 (1993).
9. KALECHMAN, Y., STRASSMANN, G., ALBECK, M. and SREDNI, B., Upregulation by AS101 of Fas/APO-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101. J. Immunol., 161, 3536-3542 (1998).
10. KALECHMAN, Y., ZULOFF, A., ALBECK, M. and SREDNI, B., Role of endogenous cytokine secretion in radioprotection conferred by the immunomodulator AS101. Blood, 85, 1555-1561 (1995).
11. LADEROUTE, K.R., AUSSERER, W.A., KNAPP, A.M., GRANT, T.D. and SUTHERLAND, R.M., Epidermal growth factor modifies cell cycle control in A432 human spontaneous carcinoma cells damaged by ionizing radiation. Cancer Res., 54, 1407-1413 (1994).
12. LATINIS, K.M., CARR, L.L., PETERSON, E.J., NORIAN, L.A., ELIASON, S.L. and KORETZKY, G.A., Regulation of CD95 Fas ligand expression by TCR-mediated signalling events. J. Immunol., 158, 4602-4609 (1997).
13. OLTVAI, Z.N., MILLIMON, C.I. and KORSMEYER, S.J., Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell, 74, 609-619 (1993).
14. ROWINSKY, E.K., Update on the antitumor activity of paclitaxel in clinical trials. Ann. Pharmacother., 28, SI8-S23 (1994).
15. ROWINSKY, E.K. and DONEHOWER, R.C., Anti-microtubule agents. In: V.T. DeVita, S. Hellman and S.A. Rosenberg (eds.), Cancer. Principles and Practice of Oncology (5th ed.), pp. 475-476, Lippincott-Raven, Philadelphia (1997).
16. SREDNI, B., ALBECK, M., TICHLER, T., SHANI, A., SHAPIRA, J., BRUDERMAN, I., CATANE, R., KAUFMAN, B. and KALECHMAN, Y., Bone marrovv sparing and prevention of alopecia by AS101 in NSCL cancer patients treated with carboplatin and etoposide. J. clin. Oncol., 13, 2342-2353 (1995).
17. SREDNI, B., CASPI, R.R., KLEIN, A., KALECHMAN, Y., DANZIGER, Y., BEN YA'AKOV, M., TAMARI, T., SHALIT, F. and ALBECK, M., A new immunomodulating compound (AS101) with potential therapeutic application. Nature (Lond.) 330, 173-176 (1987).
18. SREDNI, B., TICHLER, T., SHANI, A., CATANE, R., KAUFMAN, B., STRASSMANN, G., ALBECK, M. and KALECHMAN, Y., Predominance of TH1 response in tumor bearing mice and cancer patients treated with AS101. J. nat. Cancer Inst., 88, 1276-1284 (1996).
19. SRIVASTAVA, R.K., SRIVASTAVA, A.R., KORSMEYER, M.N., CHO-CHUNG, Y.S. and LONGO, D., Involvement of microtubules in the regulation of Bcl-2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell. Biol., 18, 3509-3517 (1998).
20. WANG, T., WANG, H., ICHIJO, H., GIANNAKAKOU, P., FOSTER, T.F. and WIMALASENA, J., Microtubule interfering agents activate c-jun N-terminal kinase/stress-activated protein kinase through both ras and apoptosis signal-regulating kinase pathways. J. biol. Chem., 273, 4928-4936 (1998).